Royalty Pharma plc RPRX
68.68 USD +0.16 (+0.23%)
Regular-session close
69.71 +1.03 +1.50%
Pre-market · Nov 18, 4:43 AM ET
67.62 Day range 68.77
37.31 52-week range 70.37
- YTD
- +77.74%
- 1 year
- +75.38%
News
seekingalpha.com Royalty Pharma plc (RPRX) Presents at UBS Global Biopharma Conference 2026 Transcript Royalty Pharma plc (RPRX) Presents at UBS Global Biopharma Conference 2026 Transcript
defenseworld.net Royalty Pharma PLC $RPRX Shares Sold by Eurizon Capital SGR S.p.A. Eurizon Capital SGR S.p.A. cut its position in shares of Royalty Pharma PLC (NASDAQ: RPRX) by 57.8% during the undefined quarter, according to the company in its most recent filing with the SEC. The…
defenseworld.net 310,727 Royalty Pharma PLC $RPRX Shares Sold by Alps Advisors Inc. Alps Advisors Inc. trimmed its stake in shares of Royalty Pharma PLC (NASDAQ: RPRX) by 98.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange…
fool.com Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE? Lower fees and a steadier beta set one healthcare ETF apart, while the rival fund's richer dividend could sway income-focused investors.
benzinga.com Here's How Much $100 Invested In Royalty Pharma 15 Years Ago Would Be Worth Today Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 15 years by 6.93% on an annualized basis producing an average annual return of 19.95%. Currently, Royalty Pharma has a market…
globenewswire.com Royalty Pharma to present at the UBS Global Biopharma Conference NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference on Tuesday, November…
seekingalpha.com Royalty Pharma: Stronger Royalty Growth Supports Further Upside Royalty Pharma's Q3 royalty receipts increased 9% to $883 million, led by strong growth in Tremfya, Voranigo, and Evrysdi. Vertex now accounts for approximately 25% of royalty receipts, indicating…benzinga.com Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $78 Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $70 to $78.
benzinga.com Royalty Pharma Q3 Adj. EPS $1.21 Beats $1.18 Estimate, Sales $690.000M Miss $796.528M Estimate Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $1.18 by 2.54 percent. This is a 3.42 percent increase over earnings of $1.17…
benzinga.com Here's How Much $100 Invested In Royalty Pharma 10 Years Ago Would Be Worth Today Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 32.09% on an annualized basis producing an average annual return of 45.51%. Currently, Royalty Pharma has a market…
benzinga.com ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test ARM Holdings headlines Wednesday’s reports, with investors looking for evidence that AI-related demand can support the chip designer after a sharp stock pullback. McDonald’s, Novo Nordisk, Uber…
